Procarta is developing novel antibacterials generated using an adaptable DNA-based platform to counter the unmet challenge in the clinic - the rise of drug-resistant bacterial strains. A

snare™

antibacterial to treat MRSA is in pre-clinical development. Similar treatments are being developed for Gram-negative infections (P. aeruginosa, E. coli and K. pneumoniae) as well as the causative agent for anthrax (B. anthracis). The platform is highly adaptable and can be used to create antibacterials active against single pathogens, to be Broad-spectrum or different

snare™

used in combination to treat complex infections.

• Rapid discovery

• Multiple novel targets

• Designer spectrum